Covid19THROMBO-VAXCOVNCT04889326
Collection of the Thrombo-VaxCov Cohort
An observational study of Covid19 and SARS-CoV Infection, run by University Hospital, Lille at 1 site in France.
Trial summary
In the context of anti-Covid19 vaccination, atypical thrombosis have occured and potential link with vaccination is under investigation. This study collect clinical and biological data of all atypical thrombosis occurring within 4 weeks after antiCovid vaccination. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Covid19, SARS-CoV Infection, Venous Thrombosis
- What is being tested?
- Retrospective data and biological samples
- How many people
- 0 participants
- Where
- 1 siteFrance
- Study dates
- 2 Apr 2021to 1 May 2023
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: patient hospitalized with atypical thrombosis occurring within 4 weeks of anticovid vaccination
Who may be able to join
- atypical thrombosis symptoms onset within 4 weeks of vaccination
Who cannot join
- children
Trial locations and contacts
1 site in 1 country.
About this study
Official title: A Clinico-biological Database on Atypical Venous Thrombosis in the Context of anticovid19 Vaccination
In the context of anti-Covid19 vaccination, atypical thrombosis have occured and potential link with vaccination is under investigation.
This study collect clinical and biological data of all atypical thrombosis occurring within 4 weeks after antiCovid vaccination.
Read the detailed description
In the context of anti-Covid19 vaccination, atypical thrombosis have occurred and potential links with vaccination is under investigation. In France, the study collect clinical and biological data of all atypical thrombosis occurring within 4 weeks after anti-Covid vaccination.
- Conditions
- Covid19, SARS-CoV Infection, Venous Thrombosis, Thrombocytopenia, Vaccination; Complications
- Being tested
- Retrospective data and biological samples
- Medical subject headings
- COVID-19, Severe Acute Respiratory Syndrome, Venous Thrombosis, Thrombocytopenia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Retrospective data and biological samplesOther
Analysis of data and biological samples collected during hospitalization:
| Study group | Role | What they receive |
|---|---|---|
| patient hospitalized with atypical thrombosis within 4 weeks of anti-covid vaccination | Not described Receives: Other: Retrospective data and biological samples |
What is being measured
The primary outcome is the main question the study is designed to answer.
Functional outcome (modified rankin scale)
Measured: through study completion, an average of 1 years
Secondary outcomes (2)
Recurrent vascular events
Measured: through study completion, an average of 1 years
Mortality
Measured: through study completion, an average of 1 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 May 2021
- Study start2 Apr 2021
- Primary completion1 May 2023
- Study completion1 May 2023
Why it stopped: COVID
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Covid19Studies of the same condition, open and under way.
- More trials run by University Hospital, LilleThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 0 participants (actual)
Sponsor and investigators
- Lead sponsor
- University Hospital, Lille
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Charlotte Cordonnier, MD,PhD, Principal investigator, University Hospital, Lille
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04889326
- Sponsor's protocol ID
- ECH_2021_cb
- Acronym
- THROMBO-VAXCOV
- Status last verified
- May 2026
- First submitted
- 27 Apr 2021
- Last updated
- 22 May 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 22 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Clinico-biological Database on Atypical Venous Thrombosis in the Context of anticovid19 Vaccination
- ClinicalTrials.gov ID
- NCT04889326
- Acronym / sponsor ID
- THROMBO-VAXCOV / ECH_2021_cb
- Conditions
- Covid19, SARS-CoV Infection, Venous Thrombosis, Thrombocytopenia, Vaccination; Complications
- Study type
- Observational
- Recruitment status
- WithdrawnReason stopped: COVID
- Enrolment
- 0 participants (actual)
- Lead sponsor
- University Hospital, LilleUniversity, hospital or other
- Study start
- 2 Apr 2021 (actual)
- Primary completion
- 1 May 2023 (actual)
- Study completion
- 1 May 2023 (actual)
- First posted
- 17 May 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
In the context of anti-Covid19 vaccination, atypical thrombosis have occured and potential link with vaccination is under investigation.
This study collect clinical and biological data of all atypical thrombosis occurring within 4 weeks after antiCovid vaccination.
Detailed description
In the context of anti-Covid19 vaccination, atypical thrombosis have occurred and potential links with vaccination is under investigation. In France, the study collect clinical and biological data of all atypical thrombosis occurring within 4 weeks after anti-Covid vaccination.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| patient hospitalized with atypical thrombosis within 4 weeks of anti-covid vaccination | – | Other: Retrospective data and biological samples |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- patient hospitalized with atypical thrombosis occurring within 4 weeks of anticovid vaccination
Key inclusion criteria (1 listed)
- atypical thrombosis symptoms onset within 4 weeks of vaccination
Key exclusion criteria (1 listed)
- children
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Retrospective data and biological samplesAnalysis of data and biological samples collected during hospitalization: | Other | patient hospitalized with atypical thrombosis within 4 weeks of anti-covid vaccination |
Primary outcome
Functional outcome (modified rankin scale)
Time frame: through study completion, an average of 1 years
2 secondary outcomes
Recurrent vascular events
Time frame: through study completion, an average of 1 years
Mortality
Time frame: through study completion, an average of 1 years
Results and safety
The study was withdrawn before enrolling participants, so there are no results.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 May 2026.
- Individual participant dataSharing planned: Yes
Related trials for Covid19
Not yet recruitingPhase 1
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Post-Acute COVID-19 Syndrome
Active, not recruitingPhase 1
A Safety and Immunogenicity Trial of OCU500, ChAd36 Vector Encoding SARS-CoV-2 Spike Vaccine Via Intranasal and Inhalational Routes in Previously Vaccinated Adults
COVID-19
Active, not recruiting
Intervention to Address Disparate Mental Health Consequences of COVID-19 Pandemic on Latinx and African Newcomers
Mental Health Issue, Mental Health Disorder
Recruiting
Home-Based Exercise Tele-Rehabilitation After COVID-19
Post SARS-CoV2 (COVID-19)
Not yet recruitingPhase 1
A Safety, Reactogenicity and Immunogenicity Trial of RVX-sCPD9 Booster Intranasal COVID-19 Vaccine
COVID -19
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Charlotte Cordonnier, MD,PhD principal investigator
University Hospital, Lille
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Covid19 and SARS-CoV Infection, run by University Hospital, Lille at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: withdrawn, as of the sponsor's last update on 22 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study was withdrawn before enrolling participants, so there are no results.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Functional outcome (modified rankin scale) (time frame: through study completion, an average of 1 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 May 2026.